Donate

Degarelix or Leuprolide – Today’s Question Explored

There are many different types of drugs used for hormone therapy in the treatment of prostate cancer. One of the newer classes of drugs include the GnRH antagonists. Degarelix (aka Firmagon) is the one drug in this class that is currently approved for prostate cancer. Degarelix, like the other hormone therapy drugs, was developed to [...]

An Evaluation of Testosterone Flare During a Transition from Degarelix to Leuprolide in Men on ADT *

Many men with advanced prostate cancer who are on hormone therapy (ADT) use one of the newer drugs, degarelix (Firmagon) to achieve a state of castration. Degarelix is considered a superior drug for initiating ADT because it is not accompanied with a PSA flare that is common with the older luteinizing hormone-releasing hormone (LHRH) agonists [...]

Degarelix Monotherapy vs. Luteinizing Hormone-Releasing Hormone Agonists Plus Antiandrogen Flare Protection For Men With Advanced Prostate Cancer *

There are a number of different flavors of hormone therapy (ADT) used to treat advanced prostate cancer. However, they could be summed up and put into two different categories. 1- The use of luteinizing hormone-releasing hormone (LHRH) agonist therapy (drugs like Lupron and Zoladex) along with short term antiandrogen (AA) flare protection 2- Degarelix, a [...]

Efficacy of Long-Term Treatment of > 5-10 Years with the LHRH Drug Leuprorelin (Lupron)

Popular culture tells us that primary androgen deprivation therapy with leuprorelin acetate (Lupron) will not work for longer than two years!  This is a significant and very problematic statement given that all of us with metastatic prostate cancer rely on delaying the move to any other treatments, especially given their cost to the quality of [...]

Degarelix Proves to be the Superior Hormone Deprivation Treatment (ADT) for Men with Advanced Prostate Cancer

Based on six recent retrospective analyses comparing the gonadotropin-releasing hormone (GnRH) antagonist degarelix against the traditional luteinizing hormone-releasing hormone (LHRH) agonists (i.e. Zoladex, Lupron etc.) men with advanced prostate cancer experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events. The six analyses compared data from randomized trials that [...]

New Data on Long-Term Use of Firmagon® (degarelix) For Men with Advanced Hormone Dependant Prostate Cancer

New data, published September 1 in the Journal of Urology, shows that Firmagon® (degarelix) which is a gonadotropin-releasing hormone therapy (GnRH) given to men with advanced prostate cancer may be superior to leuprolide when used over three years. This new study (CS21A) was an open-label extension of the Phase III study (CS21) in which Firmagon® [...]

Study Finds that Degarelix is Superior to Leuprolide

According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]

Combined Androgen Blockade (ADT2) with Bicalutamide (Casodex) For Advanced Prostate Cancer Provides Increased Survival Time

One of the first treatments used when diagnosed with advanced or recurrent prostate cancer is hormone therapy. Hormone therapy (androgen blockade) is a systematic treatment, or it treats the cancer through the entire body. Prostate cancer that is believed to be in the gland is treated with a localized, focused treatment of the actual gland [...]

Go to Top